News & Updates

Use of candesartan is both safe and effective, showing promise in the prevention of migraine headaches, suggests a study in the Philippines.

A large, multicohort study of cognitively unimpaired older adults has found that higher plasma p-tau217 levels are consistently associated with greater risk of progression to cognitive impairment and faster rates of cognitive decline, providing time-specific absolute risk estimates and supporting the potential of p-tau217 for prognostic model development.

A pooled analysis presented at AAIC^® 2026 demonstrated a consistent association between higher levels of plasma phosphorylated tau 217 (p-tau217) and an increased risk of clinical progression and accelerated cognitive decline in a large cohort of older adults without cognitive impairment.

O-linked N-acetylglucosaminidase inhibition with ceperognastat falls short of slowing disease progression in patients with early Alzheimer’s disease (AD), according to a phase II study.

Adherence to healthy dietary patterns offers no significant effect on the long-term risk of cognitive decline in a population-based cohort of older Singaporeans, researchers have found.

Treatment with oral venglustat demonstrates superior neurologic outcomes compared with standard enzyme replacement therapy (ERT) in patients with Gaucher disease type 3 (GD3), according to the phase III LEAP2MONO trial presented at EHA 2026.